Buscar
Akoustis Technologies Ord Shs
AKTSAñadir a la lista de seguimiento
27.050USD
+0.400+1.50%
Cierre 09-04 16:00（ET）
1.50BCap. mercado
PérdidaP/E TTM
Más Datos de Akoustis Technologies Ord Shs Compañía
Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.
Perfil de Akoustis Technologies Ord Shs
Símbolo de cotizaciónAKTS
Nombre de la empresaAktis Oncology Inc
Fecha de salida a bolsaJan 09, 2026
Director ejecutivoRoden (Matthew)
Número de empleados117
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 09
Dirección17 Drydock Avenue
CiudadBOSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02210
Teléfono13026587581
Sitio Webhttps://www.aktisoncology.com/
Símbolo de cotizaciónAKTS
Fecha de salida a bolsaJan 09, 2026
Director ejecutivoRoden (Matthew)
Ejecutivos de Akoustis Technologies Ord Shs
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
91.99K
-0.01%
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
91.99K
-0.01%
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
91.99K
-0.01%
Mr. Paul L. Feldman, Ph.D.
Mr. Paul L. Feldman, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Tyler Benedum, Ph.D.
Mr. Tyler Benedum, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Todd Foley
Mr. Todd Foley
Chairman of the Board
Chairman of the Board
--
-100.00%
Ms. Shulamit Ron-Bigger, Ph.D.
Ms. Shulamit Ron-Bigger, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Kyle D. Kuvalanka
Mr. Kyle D. Kuvalanka
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Akos Czibere, M.D.
Mr. Akos Czibere, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ken Herrmann, M.D.
Mr. Ken Herrmann, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
91.99K
-0.01%
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
91.99K
-0.01%
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
91.99K
-0.01%
Mr. Paul L. Feldman, Ph.D.
Mr. Paul L. Feldman, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Tyler Benedum, Ph.D.
Mr. Tyler Benedum, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Todd Foley
Mr. Todd Foley
Chairman of the Board
Chairman of the Board
--
-100.00%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Akoustis Technologies Ord Shs?
Los cinco principales accionistas de Akoustis Technologies Ord Shs son: Mr. Matthew (Matt) Roden, Ph.D.
¿Cuántas instituciones poseen acciones de Akoustis Technologies Ord Shs (AKTS)?
A fecha de 2026Q1, 195 instituciones poseen acciones de Akoustis Technologies Ord Shs, con un valor de mercado combinado de aproximadamente 27.52M, lo que representa el 51.47% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1127277.00.